DBV Technologies proudly welcomes Mr. David Schilansky as its new Chief Financial Officer

Bagneux, December 6, 2011 - DBV Technologies announces the arrival of David Schilansky – starting December 19 - as Chief Financial Officer and as such, will supervise all financial activities of the company as well as partnerships and Business Development initiatives. David will be a member of the Executive Committee.

"The integration of David Schilansky to DBV's management team will allow the company to pursue its structuration and improve its governance. It allows furthermore, for DBV to set itself into gear for the next essential development steps that will take place during 2012. The arrival of David brings an essential contribution to the company at a time when DBV Technologies wants to give a new impulse to its development in Europe and in the United States" has said Pierre-Henri Benhamou, CEO of DBV Technologies.

Prior to joining DBV Technologies, David Schilansky was Deputy CFO of Ipsen, that he joined in 2006. David has held important positions within the Finance & Administrative Department, and participated in several external growth transactions as well as the creation of an Investor Relations Department. In 2011, David also served as interim CFO and member of the Executive Committee. Prior to joining Ipsen, David spent three years at UBS Warburg, in Mergers & Acquisitions, and three years at Thomson as Investor Relations’ Officer. David graduated both from Paris Dauphine University and the Imperial College London.

About DBV Technologies
DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food and pediatric allergies. Allergen-specific immunotherapy is the only strategy that treats the underlying cause of an allergic disorder. DBV’s proprietary epicutaneous patch technology — VIASKIN® — involves maintaining an allergen on the skin of an allergic subject for repeated and prolonged periods in order to obtain clinical desensitization.

About VIASKIN® Technology
When the VIASKIN patch containing a specific allergen is applied to the skin of a patient with an IgE-mediated allergy — such as peanuts or milk — the allergens are deposited locally on the skin and are captured specifically by the skin’s immuno-competent cells. For more information, please visit our website: www.dbv-technologies.com

About VIASKIN® Peanut Immunotherapy
A Clinical development is on-going. For more information please visit our website: http://www.dbv-technologies.com/.

NOTE: VIASKIN® Peanut is only for investigational use at the moment in the USA and in Europe.

###